# Combination Study of SV-BR-1-GM With Retifanlimab

> **NCT03328026** · PHASE1,PHASE2 · COMPLETED · sponsor: **BriaCell Therapeutics Corporation** · enrollment: 36 (actual)

## Conditions studied

- Breast Cancer
- Breast Neoplasm
- Metastatic Breast Cancer
- Breast Cancer Metastatic

## Interventions

- **BIOLOGICAL:** SV-BR-1-GM
- **DRUG:** Low dose cyclophosphamide
- **DRUG:** Interferon Inoculation
- **DRUG:** retifanlimab

## Key facts

- **NCT ID:** NCT03328026
- **Lead sponsor:** BriaCell Therapeutics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-16
- **Primary completion:** 2026-03-24
- **Final completion:** 2026-03-24
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03328026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03328026, "Combination Study of SV-BR-1-GM With Retifanlimab". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03328026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*